

COMy 2022 Scientific Program

All program timing in CEST

Live broadcast from Paris:

Thursday, May 12 - 09:00-19:45

Friday, May 13 - 08:30-19:30

Saturday, May 14 - 08:30-17:30

Broadcast only:

Sunday, May 15 - 09:00-13:15

Day 1, Thursday, May 12th	
09:00-10:15	Antibody-drug Conjugates in Relapsed/Refractory Multiple Myeloma: from bench to bedside <i>Industry-supported independent symposium</i>
10:15-10:35	Coffee Break
10:35-10:45	COMy 2022 kick-off: Welcome by Congress Co-Chairs
10:45-12:00	Session 1: How to assess disease risk
	Chairs: Hervé Avet-Loiseau , France & Irene Ghobrial , USA
10:45-11:00	Diagnostic criteria and state of the art work-up Shaji Kumar , USA
11:00-11:15	What is standard risk, high risk and ultra-high risk? Hervé Avet-Loiseau , France
11:15-11:30	The role of the transcriptome Jill Corre , France
11:30-11:45	The role of imaging Elena Zamagni , Italy
11:45-12:00	Role of precursor conditions Irene Ghobrial , USA
12:00-12:30	Lunch Break
12:30-13:30	Taking centre stage: is chromosome 1 the new headline in multiple myeloma? <i>Industry-supported lunch symposium</i>
13:30-13:40	Technical Break
13:40-15:00	Session 2: Mechanisms of resistance in myeloma
	Moderators: Paola Neri , Canada & Niels van de Donk , The Netherlands
13:40-13:55	Resistance to IMiDs Nizar Bahlis , Canada
13:55-14:10	Resistance to proteasome inhibitors Marc Raab , Germany
14:10-14:25	Resistance to antibodies Niels van de Donk , The Netherlands
14:25-14:40	Resistance to immune therapies Paola Neri , Canada
14:40-15:00	Roundtable discussion - <i>All Speakers and Moderators</i>
15:00-16:30	Session 3: Frontline therapy of transplant-eligible patients
	Moderators: Nizar Bahlis , Canada & Philippe Moreau , France
15:00-15:15	Overview of induction regimens Philippe Moreau , France
15:15-15:30	Role of consolidation (including double auto-transplant) Michele Cavo , Italy
15:30-15:45	Special approaches in high-risk cytogenetics Pieter Sonneveld , The Netherlands

15:45-16:30	Roundtable discussion - <i>All Speakers and Moderators</i>
16:30-17:00	Coffee Break
17:00-18:30	It's MMy Life: Your specialty, my world <i>Industry-supported symposium</i>
18:30-18:45	Technical Break
18:45-19:45	Session 4: Plenary lectures
	Chair: Thierry Facon , France
18:45-19:05	Advances in Waldenström macroglobulinemia Steven Treon , USA
19:05-19:25	iStopMM study - the impact of nationwide screening Sigurður Kristinnsson , Iceland
19:25-19:45	Q & A

Day 2, Friday, May 13 th	
08:00-08:30	Good morning coffee
08:30-09:00	Artificial Intelligence for precision medicine in Multiple Myeloma <i>Industry-supported plenary presentation</i>
09:00-09:15	Technical Break
09:15-10:15	Session 5: The IFM session
	Chair: Philippe Moreau , France
09:15-09:35	The IFM strategy for non-transplant eligible patients Salomon Manier , France
09:35-09:55	The IFM strategy for transplant eligible patients Cyrille Touzeau , France
09:55-10:15	MRD and clonal evolution: the latest IFM data Jill Corre , France
10:15-11:15	Session 6: Updates from the recent frontline clinical trials
	Chairs: Francesca Gay , Italy & Cyrille Touzeau , France
10:15-10:30	OPTIMUM/MUK9 Martin Kaiser , UK
10:30-10:45	CONCEPT Katja Weisel , Germany
10:45-11:00	FORTE Francesca Gay , Italy
11:00-11:15	MASTER Luciano Costa , USA
11:15-12:30	Session 7: Treatment of non-transplant eligible patients
	Moderators: Thierry Facon , France & Kwee Yong , UK
11:15-11:30	Frailty assessment Alessandra Larocca , Italy
11:30-11:45	Standard of care therapy Thierry Facon , France
11:45-12:00	The patient perspective Kwee Yong , UK
12:00-12:30	Roundtable discussion - <i>All Speakers and Moderators</i>
12:30-13:00	Lunch Break
13:00-14:15	Elevating standard of care in MM: unlocking the potential of novel BCMA combinations <i>Industry-supported lunch symposium</i>
14:15-14:25	Technical Break

14:25-16:10	Session 8: Management of special clinical situations
	Moderators: Graham Jackson , UK & Michel Delforge , Belgium
14:25-14:40	COVID-19 vaccination in myeloma: where do we stand? Heinz Ludwig , Austria
14:40-14:55	Practical considerations when using anti-CD38 antibodies Torben Plesner , Denmark
14:55-15:10	Management of renal impairment Joan Bladé , Spain
15:10-15:25	Infection prophylaxis Graham Jackson , UK
15:25-15:40	Cardiac complications Michel Delforge , Belgium
15:40-15:55	Guidelines for the use of bisphosphonates Evangelos Terpos , Greece
15:55-16:10	Roundtable discussion - <i>All Speakers and Moderators</i>
16:10-16:30	Coffee Break
16:30-18:00	Clinical utility of MRD for MM patients <i>Industry-supported symposium</i>
18:00-18:10	Technical Break
18:10-19:15	Session 9: Plenary lectures
	Chair: Jean-Luc Harousseau , France
18:10-18:35	MRD evaluation: How, When and for which goal? Jesús San Miguel , Spain
18:35-19:00	Genomics of myeloma: what's new? Nikhil Munshi , USA
19:00-19:15	Q & A
19:15-19:30	Awards Ceremony: Presented by Congress Co-Chairs

Day 3, Saturday, May 14th	
08:00-08:30	Good morning coffee
08:30-09:00	Innovation for Patients with Relapsed/Refractory Multiple Myeloma: Development of TALEN gene-edited Allogeneic CAR-T Therapies Targeting CS1 <i>Industry-supported plenary presentation</i>
09:00-09:10	Technical Break
09:10-10:00	Session 10: The IMS session: Global view of state-of-the-art in myeloma - What are our strategies?
	Chairs: Mohamad Mohty , France; Philippe Moreau , France & Nikhil Munshi , USA
09:10-09:15	Introduction Nikhil Munshi , USA
09:15-09:25	Strategies for US Co-operative trials Saad Usmani , USA
09:25-09:35	Strategies for European trials Cyrille Touzeau , France
09:35-09:45	Strategies for Asia-Pacific and Latin America Andrew Spencer , Australia
09:45-10:00	What IMS can do for all Philippe Moreau , France
10:00-10:50	Session 11: Hot debates
	Chair: Mohamad Mohty , France
10:00-10:25	Debate: MRD to drive therapy

10:00-10:10	Pro: Bruno Paiva , Spain
10:10-10:20	Con: Meral Beksac , Turkey
10:20-10:25	Discussion
10:25-10:50	Debate: Immune therapies replacing ASCT frontline
10:25-10:35	Pro: Paul Richardson , USA
10:35-10:45	Con: Arnon Nagler , Israel
10:45-10:50	Discussion
10:50-11:20	Coffee Break
11:20-12:20	Session 12: Novel agents for relapse: the latest data about ...
	Chairs: Meral Beksac , Turkey & Enrique Ocio , Spain
11:20-11:30	Antibodies and IMiDs combinations for first relapse Xavier Leleu , France
11:30-11:40	CelMods Sagar Lonial , USA
11:40-11:50	XPO inhibitors Nizar Bahlis , Canada
11:50-12:00	Manipulation of apoptotic pathways Cyrille Touzeau , France
12:00-12:10	HDAC inhibitors Enrique Ocio , Spain
12:10-12:20	Antibody-drug conjugates Suzanne Trudel , Canada
12:20-13:00	Lunch Break
13:00-14:00	Giving new hope to patients with Multiple Myeloma: How? <i>Industry-supported lunch symposium</i>
14:00-14:10	Technical Break
14:10-15:45	Session 13: Immune therapy in relapsed/refractory myeloma
	Moderators: Hermann Einsele , Germany & Sagar Lonial , USA
14:10-14:25	CAR T cells Noopur Raje , USA
14:25-14:40	Bi-specific antibodies Ajai Chari , USA
14:40-14:55	Management of CRS and neurotoxicity Salomon Manier , France
14:55-15:10	Integrating immune therapies and autologous transplantation Hermann Einsele , Germany
15:10-15:25	Immune therapies at first relapse: pro and con Paul Richardson , USA
15:25-15:45	Roundtable discussion - <i>All Speakers and Moderators</i>
15:45-16:15	Coffee Break
16:15-17:25	Session 14: Plenary lectures
	Moderators: Mohamad Mohty , France & Arnon Nagler , Israel
16:15-16:35	The requirements for operational cure Jean-Luc Harousseau , France
16:35-17:05	Multiple myeloma cured in 2030: what are the next steps? Kenneth Anderson , USA
17:05-17:25	Roundtable discussion - <i>All Speakers and Moderators</i>
17:25-17:30	In-Person Meeting Conclusions and Adjournment: Congress Co-Chairs

Day 4, Sunday, May 15th - VIRTUAL ONLY	
09:00-10:50	Session 15: Abstract communications
	Chairs: Mohamad Mohty , France; Thierry Facon , France & Arnon Nagler , Israel
09:00-09:10	AN ONGOING PHASE I STUDY SHOWS CLINICALLY MEANINGFUL ACTIVITY AND MANAGEABLE SAFETY OF CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE] Thierry Facon , France
09:10-09:20	EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CYTOKINE RELEASE SYNDROME WITH REGN5458, A BCMAxCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA James Hoffman , USA
09:20-09:30	INSURE: A GLOBAL POOLED ANALYSIS (INSIGHT MM, UVEA-IXA, AND REMIX) OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE Xavier Leleu , France
09:30-09:40	Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM) Philippe Moreau , France
09:40-09:50	DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN (BELAMAF) PLUS STANDARD OF CARE (SOC) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TI-NDMM) Saad Usmani , USA
09:50-10:00	CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B Niels van de Donk , The Netherlands
10:00-10:10	UPDATE FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF MODAKAFUSP ALFA (TAK-573), A FIRST-IN-CLASS IMMUNOCYTOKINE, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) Dan T. Vogl , USA
10:10-10:20	CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS PHYSICIAN'S CHOICE OF TREATMENT (PCT): A META-ANALYSIS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) Katja Weisel , Germany
10:20-10:50	Q & A
10:50-11:00	Break
11:00-12:55	Session 16: Special lectures
	Chairs: Mohamad Mohty , France; Thierry Facon , France & Arnon Nagler , Israel
11:00-11:20	MGUS: diagnosis, risk stratification and management Vincent Rajkumar , USA
11:20-11:35	Treatment of the ultra-frail patients Sonja Zweegman , The Netherlands
11:35-11:50	Maintenance approaches post-transplant María-Victoria Mateos , Spain
11:50-12:00	Antibodies and proteasome inhibitors combinations for first relapse Saad Usmani , USA
12:00-12:20	Therapy at first relapse: current data and perspectives Meletios Dimopoulos , Greece



12:20-12:35	Defining disease aggressiveness during therapy Gareth Morgan, USA
12:35-12:55	Advances in AL amyloidosis Giampaolo Merlini, Italy
12:55-13:15	COMy 2022 Meeting Conclusions: Final roundtable virtual discussion <i>With:</i> <i>Jill Corre, France</i> <i>Luciano Costa, USA</i> <i>Thierry Facon, France</i> <i>Francesca Gay, Italy</i> <i>Jean-Luc Harousseau, France</i> <i>Giampaolo Merlini, Italy</i> <i>Mohamad Mohty, France</i> <i>Arnon Nagler, Israel</i> <i>Vincent Rajkumar, USA</i>